Is it safe to use ProHance (gadoteridol) in a patient with chronic kidney disease stage 4 (eGFR 15‑29 mL/min/1.73 m²), and what precautions are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ProHance Use in CKD Stage 4

ProHance (gadoteridol) can be safely administered in patients with CKD stage 4 (eGFR 15-29 mL/min/1.73 m²) at standard doses, as it is a Group II macrocyclic gadolinium-based contrast agent with an exceedingly low risk of nephrogenic systemic fibrosis (NSF). 1

Risk Stratification

ProHance is classified as a Group II GBCM (very low NSF risk) based on its macrocyclic structure 1. The evidence demonstrates:

  • Zero confirmed unconfounded NSF cases in 4,931 patients with stage 4 or 5 CKD who received Group II agents 2
  • Upper bound of 95% CI for NSF risk: 0.07% overall for Group II agents 2
  • For gadoteridol specifically: 0 cases in 230 patients (upper bound 1.59%) 2
  • A dedicated hemodialysis study found zero NSF cases in 141 patients with 198 gadoteridol exposures 3

Administration Protocol for CKD Stage 4

Dosing:

  • Use standard dose: 0.2 mL/kg (0.1 mmol/kg) as rapid IV infusion 4
  • Do NOT use reduced doses (half or quarter dosing is not recommended) 5
  • Avoid repeat injections within 24 hours unless urgent 1

Pre-Administration Requirements:

  • Document eGFR through laboratory testing 4
  • Obtain informed consent citing the exceedingly low (<0.07%) NSF risk 5
  • No prophylactic measures are indicated 1

Post-Administration:

  • Do NOT initiate or alter dialysis based solely on gadoteridol administration 1
  • For patients already on hemodialysis, continue routine schedule 1
  • Prophylactic hemodialysis to prevent NSF is unproven and not recommended 4

Key Clinical Distinctions

The 2021 ACR-NKF consensus guidelines 1 fundamentally changed practice by establishing that:

  • Kidney function screening is optional for Group II agents (though already documented in your CKD stage 4 patient) 1
  • Direct radiologist-referring provider communication about NSF risk is NOT necessary for Group II agents 1
  • The diagnostic benefit of contrast-enhanced MRI typically outweighs the minimal NSF risk 2

Critical Caveats

Absolute contraindications that do NOT apply to your scenario:

  • Group I agents (gadodiamide, gadopentetate dimeglumine, gadoversetamide) remain absolutely contraindicated in CKD stage 4 5
  • ProHance is Group II, so this restriction does not apply

Situations requiring extra caution:

  • Acute kidney injury superimposed on CKD stage 4 (higher risk population) 1
  • Concomitant nephrotoxic medications (though recommendations unchanged) 1
  • Multiple urgent doses needed (subsequent doses should not be delayed for NSF concerns if clinically indicated) 1

Common pitfall to avoid: Do not withhold ProHance based on outdated guidelines that treated all GBCMs equally. The dramatic reduction in NSF cases since 2008 reflects the shift away from Group I agents 1. Recent evidence from 2025 6 supports that Group II agents should no longer be withheld in CKD patients when medically indicated.

Monitoring

  • Complete imaging within 1 hour of administration 4
  • Monitor for hypersensitivity reactions during and immediately after injection 4
  • No specific NSF monitoring protocol required, but report any suspected cases to Bracco Diagnostics (1-800-257-5181) 4

The risk-benefit analysis strongly favors proceeding with ProHance-enhanced MRI when clinically indicated in CKD stage 4, using standard dosing without special precautions beyond informed consent. 1, 2

References

3
Research

Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.

Clinical journal of the American Society of Nephrology : CJASN, 2008

Related Questions

What is the recommended protocol for using antibiotic‑impregnated beads during surgical debridement, including dosing, duration, and adjustments for renal impairment?
Can gadolinium-based MRI contrast be removed by peritoneal dialysis?
What are the 2026 KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for the evaluation and management of chronic kidney disease?
In an elderly patient with impaired renal function (eGFR ~45 mL/min/1.73 m², serum creatinine ~1.5 mg/dL), is MRI with gadolinium preferred over contrast‑enhanced CT?
With a serum creatinine of 1.98 mg/dL and an estimated glomerular filtration rate (eGFR) of 35 mL/min/1.73 m², does this indicate chronic kidney disease?
What is the pathophysiology of bruxism in adults and its relationship with emotional problems?
What is the appropriate management for a 33-year-old male, non‑smoker, without hypertension or diabetes, with low‑density lipoprotein (LDL) 141 mg/dL, non‑high‑density lipoprotein (non‑HDL) 156 mg/dL, apolipoprotein B (ApoB) 96 mg/dL, high‑density lipoprotein (HDL) 64 mg/dL, triglycerides 62 mg/dL, and lipoprotein(a) (Lp(a)) 38 nmol/L?
What is the recommended treatment for prostate cancer with pelvic lymph node recurrence after a 12‑year disease‑free interval?
What are the neuromuscular manifestations of hyperparathyroidism?
In a 39-year-old patient with fibromuscular dysplasia on bisoprolol who presents with acute 10/10 bilateral thumb pain, loss of hand function, and sudden lip angioedema, what emergency investigations and treatments—including hand/wrist radiographs, parenteral analgesia, and management of the angioedema—are indicated?
What are the recommended nighttime dosing guidelines and safety considerations for quetiapine (Seroquel) and mirtazapine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.